World's Best Scientists 2026 revealed!
Mark D. Eisner

Mark D. Eisner

D-Index & Metrics

Medicine

D-Index
88
Citations
26972
World Ranking
13213
National Ranking
6732

Mark D. Eisner publication distribution in Medicine in 2026

The chart shows the distribution of publications by all Research.com ranked scientists in the field of Medicine in 2026. The highlighted bar marks where Mark D. Eisner sits on this spectrum.

101–120 publications: 5 scientists 121–140 publications: 26 scientists 141–160 publications: 73 scientists 161–180 publications: 155 scientists 181–200 publications: 230 scientists 201–220 publications: 363 scientists 221–240 publications: 487 scientists 241–260 publications: 545 scientists 261–280 publications: 722 scientists 281–300 publications: 768 scientists 301–320 publications: 834 scientists 321–340 publications: 895 scientists 341–360 publications: 922 scientists 361–380 publications: 838 scientists 381–400 publications: 861 scientists 401–420 publications: 918 scientists 421–440 publications: 806 scientists 441–460 publications: 771 scientists 461–480 publications: 751 scientists 481–500 publications: 713 scientists 501–520 publications: 617 scientists 521–540 publications: 611 scientists 541–560 publications: 537 scientists 561–580 publications: 504 scientists 581–600 publications: 509 scientists 601–620 publications: 396 scientists 621–640 publications: 386 scientists 641–660 publications: 371 scientists 661–680 publications: 340 scientists 681–700 publications: 336 scientists 701–720 publications: 307 scientists 721–740 publications: 259 scientists 741–760 publications: 230 scientists 761–780 publications: 228 scientists 781–800 publications: 217 scientists 801–820 publications: 204 scientists 821–840 publications: 186 scientists 841–860 publications: 177 scientists 861–880 publications: 155 scientists 881–900 publications: 139 scientists 901–920 publications: 145 scientists 921–940 publications: 116 scientists 941–960 publications: 133 scientists 961–980 publications: 91 scientists 981–1,000 publications: 96 scientists 1,001–1,020 publications: 77 scientists 1,021–1,040 publications: 70 scientists 1,041–1,060 publications: 63 scientists 1,061–1,080 publications: 77 scientists 1,081–1,100 publications: 49 scientists 1,101–1,120 publications: 54 scientists 1,121–1,140 publications: 49 scientists 1,141–1,160 publications: 51 scientists 1,161–1,180 publications: 35 scientists 1,181–1,200 publications: 39 scientists 1,201–1,220 publications: 26 scientists 1,221–1,240 publications: 37 scientists 1,241–1,260 publications: 36 scientists 1,261–1,280 publications: 27 scientists 1,281–1,300 publications: 32 scientists 1,301–1,320 publications: 28 scientists 1,321–1,340 publications: 17 scientists 1,341–1,360 publications: 30 scientists 1,361–1,380 publications: 28 scientists 1,381–1,400 publications: 17 scientists 1,401–1,420 publications: 21 scientists 1,421–1,440 publications: 15 scientists 1,441–1,460 publications: 12 scientists 1,461–1,480 publications: 12 scientists 1,481–1,500 publications: 18 scientists 1,501–1,520 publications: 14 scientists 1,521–1,540 publications: 17 scientists 1,541–1,560 publications: 15 scientists 1,561–1,580 publications: 6 scientists 1,581–1,600 publications: 2 scientists 1,601–1,620 publications: 12 scientists 1,621–1,640 publications: 11 scientists 1,641–1,660 publications: 8 scientists 1,661–1,680 publications: 5 scientists 1,681–1,700 publications: 5 scientists 1,701–1,720 publications: 10 scientists 1,721–1,740 publications: 12 scientists 1,741–1,760 publications: 14 scientists 1,761–1,780 publications: 6 scientists 1,781–1,795 publications: 5 scientists 1,796+ publications: 100 scientists
101 publications 1,796+

This scientist: 221 publications — 4th percentile

4% of scientists in this discipline score the same or lower.

The last bar groups every scientist with 1,796 publications or more.

Mark D. Eisner D-index placement in Medicine in 2026

The chart shows the D-index (discipline H-index) distribution of Medicine scientists ranked by Research.com in 2026. The highlighted bar marks where Mark D. Eisner sits on this spectrum.

70–71 D-Index: 226 scientists 72–73 D-Index: 391 scientists 74–75 D-Index: 574 scientists 76–77 D-Index: 730 scientists 78–79 D-Index: 891 scientists 80–81 D-Index: 972 scientists 82–83 D-Index: 1,027 scientists 84–85 D-Index: 1,003 scientists 86–87 D-Index: 960 scientists 88–89 D-Index: 970 scientists 90–91 D-Index: 922 scientists 92–93 D-Index: 839 scientists 94–95 D-Index: 808 scientists 96–97 D-Index: 779 scientists 98–99 D-Index: 668 scientists 100–101 D-Index: 611 scientists 102–103 D-Index: 630 scientists 104–105 D-Index: 513 scientists 106–107 D-Index: 541 scientists 108–109 D-Index: 445 scientists 110–111 D-Index: 429 scientists 112–113 D-Index: 400 scientists 114–115 D-Index: 393 scientists 116–117 D-Index: 318 scientists 118–119 D-Index: 302 scientists 120–121 D-Index: 287 scientists 122–123 D-Index: 255 scientists 124–125 D-Index: 256 scientists 126–127 D-Index: 252 scientists 128–129 D-Index: 230 scientists 130–131 D-Index: 179 scientists 132–133 D-Index: 168 scientists 134–135 D-Index: 163 scientists 136–137 D-Index: 159 scientists 138–139 D-Index: 134 scientists 140–141 D-Index: 134 scientists 142–143 D-Index: 118 scientists 144–145 D-Index: 109 scientists 146–147 D-Index: 106 scientists 148–149 D-Index: 74 scientists 150–151 D-Index: 79 scientists 152–153 D-Index: 80 scientists 154–155 D-Index: 87 scientists 156–157 D-Index: 57 scientists 158–159 D-Index: 74 scientists 160–161 D-Index: 69 scientists 162–163 D-Index: 60 scientists 164–165 D-Index: 53 scientists 166–167 D-Index: 39 scientists 168–169 D-Index: 42 scientists 170–171 D-Index: 32 scientists 172–173 D-Index: 39 scientists 174–175 D-Index: 40 scientists 176–177 D-Index: 28 scientists 178–179 D-Index: 19 scientists 180–181 D-Index: 23 scientists 182–183 D-Index: 31 scientists 184–185 D-Index: 18 scientists 186–187 D-Index: 20 scientists 188–189 D-Index: 22 scientists 190–191 D-Index: 13 scientists 192–193 D-Index: 21 scientists 194–195 D-Index: 12 scientists 196–197 D-Index: 12 scientists 198–199 D-Index: 14 scientists 200–201 D-Index: 15 scientists 202–203 D-Index: 13 scientists 204–205 D-Index: 10 scientists 206–207 D-Index: 8 scientists 208–209 D-Index: 4 scientists 210–211 D-Index: 12 scientists 212–213 D-Index: 11 scientists 214–215 D-Index: 10 scientists 216 D-Index: 4 scientists 217+ D-Index: 98 scientists
70 D-Index 217+

This scientist: 88 D-Index — 36th percentile

36% of scientists in this discipline score the same or lower.

The last bar groups every scientist with 217 D-Index or more.

Overview

Mark D. Eisner is affiliated with Genentech in the United States and has contributed to multiple areas within medicine. Their work spans several subfields including cardiology and cardiovascular medicine, oncology, hematology, dermatology, and molecular biology.

Their research topics encompass a range of medical and biological subjects such as:

  • Cardiac electrophysiology and arrhythmias
  • Atrial Fibrillation Management and Outcomes
  • Erythropoietin and Anemia Treatment
  • Cancer and Skin Lesions
  • Muscle Physiology and Disorders
  • Connective Tissue Growth Factor Research
  • Fibromyalgia and Chronic Fatigue Syndrome Research

Frequent publication venues for Mark D. Eisner include:

  • British Journal of Dermatology
  • Journal of Neuromuscular Diseases
  • Circulation Research
  • Journal of Clinical Oncology
  • Therapeutic Advances in Medical Oncology

Key recent publications feature the following works:

  • Pamrevlumab, a Fully Human Monoclonal Antibody Targeting Connective Tissue Growth Factor, for Non-Ambulatory Patients with Duchenne Muscular Dystrophy, 2023, Journal of Neuromuscular Diseases
  • Restoring Atrial T-Tubules Augments Systolic Ca Upon Recovery From Heart Failure, 2024, Circulation Research
  • Efficacy and Safety of Roxadustat for Anemia in Patients Receiving Chemotherapy for Nonmyeloid Malignancies: A Randomized, Open-Label, Active-Controlled Phase III Study, 2024, Journal of Clinical Oncology
  • A novel event-free survival endpoint in locally advanced pancreatic cancer, 2021, Therapeutic Advances in Medical Oncology
  • A rash refractory to treatment, 2020, BMJ

Mark D. Eisner has collaborated frequently with a core group of coauthors including:

  • Ewa Carrier
  • Jessica L. Caldwell
  • Jessica D. Clarke
  • Charlotte Smith
  • Christian Pinali

Best Publications

  • Lebrikizumab Treatment in Adults with Asthma

    Jonathan Corren;Robert F. Lemanske;Nicola A. Hanania;Phillip E. Korenblat

  • An Official American Thoracic Society Public Policy Statement: Novel Risk Factors and the Global Burden of Chronic Obstructive Pulmonary Disease

    Mark D. Eisner;Nicholas Anthonisen;David Coultas;Nino Kuenzli

  • Pulmonary dead-space fraction as a risk factor for death in the acute respiratory distress syndrome.

    Thomas J Nuckton;James A Alonso;Richard H Kallet;Brian M Daniel

  • Lower tidal volume ventilation and plasma cytokine markers of inflammation in patients with acute lung injury.

    Polly E. Parsons;Mark D. Eisner;B Taylor Thompson;Michael A. Matthay

  • Pathogenetic and prognostic significance of altered coagulation and fibrinolysis in acute lung injury/acute respiratory distress syndrome

    Mauro Oddo;Marie-Denise Schaller;François Feihl;Vincent Ribordy

  • COPD and incident cardiovascular disease hospitalizations and mortality: Kaiser Permanente Medical Care Program.

    Stephen Sidney;Michael Sorel;Charles P. Quesenberry;Cynthia DeLuise

  • Omalizumab in severe allergic asthma inadequately controlled with standard therapy: a randomized trial.

    Nicola A. Hanania;Oral Alpan;Daniel L. Hamilos;John J. Condemi

  • Bartenders' Respiratory Health After Establishment of Smoke-Free Bars and Taverns

    Mark D. Eisner;Alexander K. Smith;Paul D. Blanc

  • Recent trends in acute lung injury mortality: 1996-2005.

    Sara E. Erickson;Greg S. Martin;J Lucian Davis;Michael A. Matthay

  • Efficacy and safety of lebrikizumab in patients with uncontrolled asthma (LAVOLTA I and LAVOLTA II): replicate, phase 3, randomised, double-blind, placebo-controlled trials

    Nicola A Hanania;Phillip Korenblat;Kenneth R Chapman;Kenneth R Chapman;Eric D Bateman

  • The occupational burden of chronic obstructive pulmonary disease

    L Trupin;G Earnest;M San Pedro;J R Balmes

  • Plasma receptor for advanced glycation end products and clinical outcomes in acute lung injury

    C S Calfee;L B Ware;M D Eisner;P E Parsons

  • Efficacy of Low Tidal Volume Ventilation in Patients with Different Clinical Risk Factors for Acute Lung Injury and the Acute Respiratory Distress Syndrome

    Mark D. Eisner;Taylor Thompson;Leonard D. Hudson;John M. Luce

  • Lifetime environmental tobacco smoke exposure and the risk of chronic obstructive pulmonary disease

    Mark D Eisner;John R. Balmes;Patricia P Katz;Laura Trupin

  • Plasma surfactant protein levels and clinical outcomes in patients with acute lung injury

    M D Eisner;P Parsons;M A Matthay;L Ware

  • A Comprehensive Study of the Direct and Indirect Costs of Adult Asthma

    Miriam G. Cisternas;Paul D. Blanc;Irene H. Yen;Patricia P. Katz

  • Significance of Von Willebrand Factor in Septic and Nonseptic Patients with Acute Lung Injury

    Lorraine B. Ware;Mark D. Eisner;B. Taylor Thompson;Polly E. Parsons

  • Influence of anxiety on health outcomes in COPD

    Mark D Eisner;Paul D Blanc;Edward H Yelin;Patricia P Katz

  • Trauma-associated lung injury differs clinically and biologically from acute lung injury due to other clinical disorders.

    Carolyn S. Calfee;Mark D. Eisner;Lorraine B. Ware;B Taylor Thompson

  • Lifetime environmental tobacco smoke exposure and the risk of chronic obstructive pulmonary disease: Environmental Health: A Global Access Science Source 2005;4:7. doi:10.1186/1476-069X-4-7 2005;12:4(1):7.

    M.D. Eisner;J. Balmes;P.P. Katz;L. Trupin

Frequent Co-Authors

Paul D. Blanc
Paul D. Blanc University of California, San Francisco
Edward H. Yelin
Edward H. Yelin University of California, San Francisco
Patricia P. Katz
Patricia P. Katz University of California, San Francisco
Carlos Iribarren
Carlos Iribarren Kaiser Permanente
Michael A. Matthay
Michael A. Matthay University of California, San Francisco
John R. Balmes
John R. Balmes University of California, Berkeley
Lorraine B. Ware
Lorraine B. Ware Vanderbilt University Medical Center
B. Taylor Thompson
B. Taylor Thompson Harvard University
Neal L. Benowitz
Neal L. Benowitz University of California, San Francisco
Carolyn S. Calfee
Carolyn S. Calfee University of California, San Francisco

If you think any of the details on this page are incorrect, let us know.

Report an issue

We appreciate your kind effort to assist us to improve this page, it would be helpful providing us with as much detail as possible in the text box below:

Related Online Degrees & Career Pathways

If you’re considering a career in Medicine but want flexible study options, online healthcare degrees can open exciting new pathways. Online nursing programs have become increasingly popular, allowing students to balance coursework with personal and professional commitments. These programs cover foundational knowledge and clinical skills vital for a career in healthcare.

For registered nurses seeking career advancement, the cheapest rn to bsn online programs offer a cost-effective way to earn a bachelor’s degree and access higher-level opportunities. Similarly, individuals aiming for leadership or research roles may explore phd in nursing online programs, which focus on advanced practice, research, and teaching.

Those with a non-nursing background who want to transition into the nursing profession may consider msn direct entry programs online. These programs accelerate entry into nursing careers by combining core skills and clinical training, making them an appealing choice for career changers.

With a variety of affordable, flexible online programs, aspiring healthcare professionals have more options than ever to launch or advance their medical careers.

Best Scientists Citing Mark D. Eisner

Trending Scientists

Recently Published Articles